Clinical trials: Obstructive Lung Disease
Chronic Obstructive Pulmonary Disease
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice…
- Trial name
- NCT06545500
- Testing
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg)
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease, COPD
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to show the superior effect of a 4 week treatment each with QVA149 versus tiotropium on lung function.
- Trial name
- FAVOR (NCT02125734)
- Testing
- QVA149, Tiotropium
- Where
- 18 sites in Germany
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair
- Trial name
- NCT00624832
- Testing
- Xolair
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
- Trial name
- OCEAN (NCT00628862)
- Testing
- Formoterol Turbuhaler® 4.5mg, Formoterol Turbuhaler® 9 mg
- Where
- 47 sites in Bulgaria, Japan and 3 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01462942
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 197 sites in Austria, Belgium and 20 more
- Volunteers
- 2,443 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1…
- Trial name
- ChAMP (NCT00295061)
- Testing
- Alpha-1 MP, alpha-1 proteinase inhibitor (human)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Grifols Therapeutics LLC
COPD
Feasibility of At-Home Handheld Spirometry
The investigators' central hypotheses predict that the handheld spirometry device will be feasible for inpatient and at-home use, and is equally efficacious at determining lung function when compared to traditional, bedside…
- Trial name
- NCT03284203
- Testing
- SpiroPD
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Chronic Obstructive Pulmonary Disease
Acute Effects of a Flutter Device in COPD
Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible, and is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles…
- Trial name
- AEFLUC (NCT01832961)
- Testing
- Flutter valve exercises, Flutter and bronchodilator exercises
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Asthma
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic…
- Trial name
- AGILE (NCT05243680)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 137 sites in United States, Australia and 12 more
- Volunteers
- 641 people
- Sponsor
- GlaxoSmithKline
Chronic Graft Versus Host Disease
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
The participant is invited to take part in this study because they have chronic Graft versus Host Disease (cGVHD) that is not responding to standard treatment with steroids.
- Trial name
- NCT01954979
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent…
- Trial name
- ARNASA (NCT05595642)
- Testing
- Astegolimab
- Where
- 348 sites in United States, Argentina and 34 more
- Volunteers
- 1,380 people
- Sponsor
- Hoffmann-La Roche
Asthma
Steroids In Eosinophil Negative Asthma
Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled…
- Trial name
- SIENA (NCT02066298)
- Testing
- Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD
- Where
- 25 sites in United States
- Volunteers
- 295 people
- Sponsor
- Milton S. Hershey Medical Center
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT01957163
- Testing
- FF, VI, UMEC
- Where
- 53 sites in United States, Argentina and 3 more
- Volunteers
- 619 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Asthma
Effects of Whole Sprouts on Airway Allergic Inflammation
The primary objective of this study is to determine if broccoli sprouts (BS) improves airway inflammatory, oxidative stress (OS), and symptoms among asthmatic adults with aeroallergen sensitization.
- Conditions
- Allergic Rhinitis, Asthma, Allergy
- Trial name
- NCT01522703
- Testing
- Broccoli Sprouts
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Johns Hopkins University
Chronic Obstructive Pulmonary Disease
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
- Trial name
- NCT01566773
- Testing
- PT001 MDI, Tiotropium Bromide
- Where
- 10 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
- Trial name
- COPD (NCT00457951)
- Testing
- Open-Label, ODSH
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
- Trial name
- NCT03311373
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Graft Versus Host Disease
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant…
- Trial name
- NCT02491359
- Testing
- Carfilzomib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Drug Use, Alcohol Use
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
This study will assess Specialized Community Disease Management (SCDM), an intervention which employs various evidence-based strategies to engage substance using co-morbid patients while in the hospital and follow them into the…
- Conditions
- Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia
- Trial name
- NCT02059005
- Testing
- Specialized Community Disease Management, Treatment As Usual
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Treatment Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.